Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1978;51:178-180
© 1978 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ZURIER, R. B.
Right arrow Articles by ROTHFIELD, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ZURIER, R. B.
Right arrow Articles by ROTHFIELD, N. F.

Systemic Lupus Erythematosus; Management During Pregnancy

ROBERT B. ZURIER, MD, THOMAS G. ARGYROS, MD, JEFFREY D. URMAN, MD, JUDITH WARREN, MD and NAOMI F. ROTHFIELD, MD

From the Rheumatic Diseases Study Group, Department of Medicine at New York University Medical Center and Division of Rheumatic Diseases, Department of Medicine at University of Connecticut School of Medicine, Farmington, Connecticut.

Abstract

The course of 27 pregnancies in 13 patients with systemic lupus erythematosus (SLE) is presented. The overall incidence of fetal wastage was 33.3%, a figure significantly higher than that observed in the general population. Although serum C3 complement levels rise during normal pregnancy, mean C3 levels remain within the normal range. Since it is a fall in complement levels in patients with SLE which may herald the onset of symptoms and provide a guide to therapy, assay of serum C3 complement levels remains a valid monitoring device in management of these patients during pregnancy. Flares of SLE during pregnancy generally should be treated vigorously with cortico-steroids rather than by therapeutic abortion. Continuation of corticosteroid treatment during the first 2 months postpartum is advised to limit the incidence of exacerbation of SLE activity following delivery.




This article has been cited by other articles:


Home page
 LupusHome page
Y Molad, T Borkowski, A Monselise, A Ben-Haroush, J Sulkes, M Hod, D Feldberg, and J Bar
Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies
Lupus, February 1, 2005; 14(2): 145 - 151.
[Abstract] [PDF]

Home page
 LupusHome page
M. Keane, C. Van De Ven, J. Lynch III, and W. McCune
Systemic lupus during pregnancy with refractory alveolar haemorrhage: recovery following termination of pregnancy
Lupus, January 1, 1997; 6(9): 730 - 733.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by the American College of Obstetricians and Gynecologists.